Peloton Therapeutics, Inc. clinical trials
Acquired by Merck & Co., Inc, Jul 2019 · source ↗
The registry lists 7 studies whose lead sponsor is Peloton Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2026.
- 7studies on the registry
- 0open to participants now
- 2reach primary completion within a year
Before and after it joined Merck & Co., Inc
- First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- 7
- First submitted after Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Peloton Therapeutics, Inc.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
2 of Peloton Therapeutics, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- 1FFeb
- MMar
- 1AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
- Feb 2027A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)belzutifan · NCT03634540
- Apr 2027A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)belzutifan · NCT03401788
Add all 2 to your calendar (.ics) → With an account.
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 16
- 17
- 318
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)7 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Merck & Co., Inc studies →
- A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active, not recruitingNCT02974738Phase 1
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)Active, not recruitingNCT03401788Phase 2
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)Active, not recruitingNCT03634540Phase 2
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)CompletedNCT03108066Phase 2
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)Active, not recruitingNCT02293980Phase 1
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) TabletsCompletedNCT03445169Phase 1
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc
- PT2385-102 Food Effect Study of PT2385 in Healthy VolunteersCompletedNCT02553356Phase 1
Sponsor listed in the registry: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Peloton Therapeutics, Inc. became part of Merck & Co., Inc